The National Institute for Health and Care Excellence (NICE) in new final guidelines has recommended Moventig (naloxegol) from AstraZeneca as...
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the FDA has accepted for review Valeant's New Drug Application...
AstraZeneca has announced that the New England Journal of Medicine has published results of two pivotal Phase III studies �...
AstraZeneca has announced that Moventig (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of...
Two Phase III trials and one safety extension trial of Naloxegol (naxolol), from AstraZeneca, in patients with non-cancer related pain...
New results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of Naloxegol (naxolol), from AstraZeneca, in patients with non-cancer...
AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik (naloxegol) in the USA. Under the terms of the...
Further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies showed that Movantik (naloxegol), from AstraZeneca, had a similar...
How should general practitioners assess patient pain and consider treatment? Read our original article investigating current advice and good clinical practice.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...